Modified albumin–bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients

Details 詳細情報について

• CRID

  1360290617674228864

• DOI

  10.1007/s10147-020-01835-2

• ISSN

  14377772

  13419625

• Web Site

  https://link.springer.com/content/pdf/10.1007/s10147-020-01835-2.pdf

  https://link.springer.com/article/10.1007/s10147-020-01835-2/fulltext.html

  https://search.jamas.or.jp/link/ui/2022035465

• Data Source

  • Crossref
  • KAKEN